[Israel, 30 November, 2023]GrayMatters Health (GMH), one of the portfolio companies of our subsidiary Corundum Neuroscience, formerly Joy Ventures, and an Israeli developer of digital self-neuromodulation therapies for mental disorders, announced that the Ministry of Health in Israel granted approval for marketing its flagship product, Prism for PTSD, the first non-invasive, self-neuromodulation adjunct digital therapy for post-traumatic stress disorder.
It is another remarkable accomplishment followed by the U.S. Food and Drug Administration (FDA) granting 510(k) Clearance in March 2023.
Furthermore, GMH was named the Prix Galien USA Best Startup 2023 winner, a prestigious U.S. award given to companies that have made noteworthy contribution in the field of life sciences. Stay tuned for more updates.
Learn more by visiting here.
About Corundum Innovation
Corundum Innovation Co., Ltd., and Corundum Ventures Ltd. (Hereafter Corundum) provide venture capital (VC) investment and consulting services to investors for both financial and strategic returns. Corundum provides flexible services to COIF’s investors for new business development in various phases with our expertise in science, technology, business development, corporate management, finance and consulting, as well as our strong network with top Israeli VC and the valuable information we can access through fund activities. Corundum’s support includes information gathering, negotiation for partnership, direct investment, market development, HR development, and fund formation.
Corundum Innovation Co., Ltd.